1.	Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSOM230C2402, 2009-016722-13, EUDRACT 2009-016722-13, NCT01137682
2.	Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: EudraCT 2006-004748-22, NCT01203306
3.	IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BJT-NEC-001, NCT01480986
4.	Everolimus Combined With Octeotride LAR to Treat Advanced GI NET Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GETNE 1003, CRAD001KES08T, NCT01567488
5.	Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AXI-IIG-02, 2011-001550-29, NCT01744249
6.	Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: LF-PB/11/04, NCT01754285